
Work Here?
Work Here?
Work Here?
Company Does Not Provide H1B Sponsorship
NanoString Technologies develops tools for spatial biology that allow researchers to map gene and protein activity directly within tissue samples. These products work by using digital barcodes and imaging to identify where specific biological markers are located without destroying the tissue's physical structure. Unlike competitors that may only look at cells in isolation, NanoString provides a complete view of how cells interact within their natural environment. The company's goal is to speed up scientific discovery in fields like cancer research and drug development by providing high-resolution insights into complex diseases.
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Seattle, Washington
Founded
2003
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$1.2B
Above
Industry Average
Funded Over
18 Rounds
Health Insurance
Paid Vacation
Paid Holidays
Performance Bonus
Company Equity
Growth Comes From InnovationEconomic growth can really come from only two sources: a larger pool of workers and/or resources or a more efficient use of available resources.With limited natural resources and declining demography, the first source of growth is increasingly unlikely to play a big role in Western economies, or in China for that matter. So growth has to come from better use of resources. And a key way to do so is through improved technology.A truck is more efficient than a horse, an excavator is more efficient than a man with a shovel, and a nuclear power plant is more efficient than burning wood or coal. More recently, technology has also started to improve intellectual professions with the rise of computers, the Internet, smartphones, software, and AI.Investing In TechnologyAny investment strategy prioritizing “tech” has probably outperformed the broader markets since the 1990s.The few wise enough investors that held on for decades to stocks of Apple, Amazon, or Tesla have likely seen returns in the 10x, 100x, or even 1000x. Today is no different.However, the most likely to grow exponentially are stocks that are just at the beginning of their journey, more than the established tech giants.So, in this article, we will explore tech companies still at an earlier stage, with large growth potential, a very long runway, and large growing markets in which to expand. We will also cover more than purely software stocks, as technological innovation also concerns hardware.10 Technology Stocks Poised for Future Growth(This list is by nature subjective and does not constitute investment advice).1
NEW YORK - The US District Court for the District of Delaware today granted 10x Genomics a permanent injunction in its patent infringement suit against NanoString Technologies (now a part of Bruker's spatial biology group).
Bruker has acquired NanoString Technologies for approximately $393 million in cash and assumed liabilities, following NanoString's bankruptcy. Bruker has formed a new division, the Bruker Spatial Biology Group, which includes NanoString, Canopy Biosciences, and Acuity Spatial Genomics. The division will maintain its original locations to avoid disruptions. Mark Munch and Todd Garland discuss Bruker's spatial biology strategy and future plans for the acquired technologies.
BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No. 2794928B1 (the “928 Patent”) in Germany (case 3 Ni 20/22). NanoString is now a Bruker business following Bruker’s asset acquisition of the businesses of NanoString Technologies, Inc on May 6th, 2024. The 928 Patent has been asserted by 10x Genomics against NanoString in patent infringement cases in Germany and before the European Unified Patent Court (UPC) involving NanoString’s CosMx Spatial Molecular Imager (SMI) products for RNA detection. The Federal Patent Court ruled that the German part of the 928 Patent is invalid. “NanoString has consistently maintained that the patents being asserted by 10x Genomics against NanoString’s CosMx SMI products are invalid
Brad Gray is stepping down from NanoString after 14 years leading the Seattle biotech company as CEO.
Find jobs on Simplify and start your career today
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Seattle, Washington
Founded
2003
Find jobs on Simplify and start your career today